Yoshimura Reiji, Mitoma Masae, Sugita Atsuko, Hori Hikaru, Okamoto Tatsuya, Umene Wakako, Ueda Nobuhisa, Nakamura Jun
Department of Psychiatry, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, Fukuoka, Japan.
Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jun 30;31(5):1034-7. doi: 10.1016/j.pnpbp.2007.03.001. Epub 2007 Mar 7.
Brain-derived neurotrophic factor (BDNF) is an important member of the neurotrophin family of growth factors, abundant in the brain and periphery. Researchers have reported that serum BDNF levels in drug-free depressed patients are lower than those of healthy controls, and have proposed that these low levels might reflect a failure of neuronal plasticity in depression. In the present study, we investigated the effects of paroxetine, an SSRI, and milnacipran, an SNRI, on serum BDNF levels in depressed patients. Serum levels of BDNF were measured by ELISA before, 4 weeks, and 8 weeks after the start of treatment with antidepressants. Forty-two patients were randomly administered paroxetine (21 cases) or milnacipran (21 cases). A negative correlation was found between serum BDNF levels and baseline Ham-D scores. The response and remission rates for each drug were not significantly different. Serum BDNF levels in responders were significantly increased 2.6- and 1.8-fold 8 weeks after treatment with paroxetine or milnacipran, respectively. These results suggest that both drugs improve the depressive state by increasing BDNF levels.
脑源性神经营养因子（BDNF）是生长因子神经营养素家族的重要成员，在脑和外周组织中含量丰富。研究人员报告称，未服用药物的抑郁症患者血清BDNF水平低于健康对照组，并提出这些低水平可能反映了抑郁症中神经元可塑性的缺失。在本研究中，我们调查了选择性5-羟色胺再摄取抑制剂（SSRI）帕罗西汀和5-羟色胺及去甲肾上腺素再摄取抑制剂（SNRI）米那普明对抑郁症患者血清BDNF水平的影响。在开始使用抗抑郁药治疗前、治疗4周和8周后，通过酶联免疫吸附测定法（ELISA）测量血清BDNF水平。42例患者被随机给予帕罗西汀（21例）或米那普明（21例）。发现血清BDNF水平与基线汉密尔顿抑郁量表（Ham-D）评分呈负相关。每种药物的有效率和缓解率无显著差异。在分别使用帕罗西汀或米那普明治疗8周后，有效患者的血清BDNF水平分别显著升高2.6倍和1.8倍。这些结果表明，两种药物均通过提高BDNF水平来改善抑郁状态。
